Patents by Inventor Francis Ennis
Francis Ennis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8067535Abstract: The present invention relates to the identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes. Three vaccinia virus CD8+ T cell epitopes restricted by the most common human M.C. class I allele, HLA-A0201, were identified. Each of these epitopes is highly conserved in vaccinia and variola viruses. In addition, the induction of the T cell responses following primary vaccination with two of these epitopes is demonstrated by the kinetics of epitope specific CD8+ T cells in 3 HLA-A0201 individuals. Two vaccinia virus CD8+ T cell epitopes restricted by another common human M.C. class I allele, HLA-B7, also were identified. Both epitopes are highly conserved in vaccinia and variola viruses. This information will be useful for the design and analysis of the immunogenicity of experimental vaccinia vaccines, and for basic studies of human T cell memory.Type: GrantFiled: September 28, 2005Date of Patent: November 29, 2011Assignee: The University of MassachusettsInventors: Masanori Terajima, John Cruz, Francis A. Ennis
-
Patent number: 7803566Abstract: The present invention relates to the identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes. Two vaccinia virus CD8+ T cell epitopes restricted by the most common human MHC class I allele, HLA-A0201 have been identified. Both epitopes are highly conserved in vaccinia and variola viruses. The induction of the T cell responses following primary vaccination is demonstrated by the kinetics of epitope specific CD8+ T cells in 3 HLA-A0201 individuals. This information will be useful for the design and analyses of the immunogenicity of experimental vaccinia vaccines, and for basic studies of human T cell memory.Type: GrantFiled: March 30, 2007Date of Patent: September 28, 2010Assignee: The University of MassachusettsInventors: Masanori Terajima, John Cruz, Francis A. Ennis
-
Publication number: 20080299603Abstract: The present invention relates to an in vitro method for determining the ability of a vaccine composition which comprises one or more antigens or a nucleic acid molecule which encodes one or more antigens to stimulate a T cell response.Type: ApplicationFiled: May 21, 2008Publication date: December 4, 2008Applicant: University of Massachusetts Medical CenterInventor: Francis A. Ennis
-
Patent number: 7387882Abstract: The present invention relates to an in vitro method for determining the ability of a vaccine composition which comprises one or more antigens or a nucleic acid molecule which encodes one or more antigens to stimulate a T cell response.Type: GrantFiled: May 13, 2005Date of Patent: June 17, 2008Assignee: University of Massachusetts Medical CenterInventor: Francis A. Ennis
-
Publication number: 20070298046Abstract: The present invention relates to the identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes. Two vaccinia virus CD8+ T cell epitopes restricted by the most common human MHC class I allele, HLA-A0201 have been identified. Both epitopes are highly conserved in vaccinia and variola viruses. The induction of the T cell responses following primary vaccination is demonstrated by the kinetics of epitope specific CD8+ T cells in 3 HLA-A0201 individuals. This information will be useful for the design and analyses of the immunogenicity of experimental vaccinia vaccines, and for basic studies of human T cell memory.Type: ApplicationFiled: March 30, 2007Publication date: December 27, 2007Inventors: Masanori Terajima, John Cruz, Francis Ennis
-
Publication number: 20070237790Abstract: The present invention relates to the identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes. Three vaccinia virus CD8+ T cell epitopes restricted by the most common human M.C. class I allele, HLA-A0201, were identified. Each of these epitopes is highly conserved in vaccinia and variola viruses. In addition, the induction of the T cell responses following primary vaccination with two of these epitopes is demonstrated by the kinetics of epitope specific CD8+ T cells in 3 HLA-A0201 individuals. Two vaccinia virus CD8+ T cell epitopes restricted by another common human M.C. class I allele, HLA-B7, also were identified. Both epitopes are highly conserved in vaccinia and variola viruses. This information will be useful for the design and analysis of the immunogenicity of experimental vaccinia vaccines, and for basic studies of human T cell memory.Type: ApplicationFiled: September 28, 2005Publication date: October 11, 2007Inventors: Masanori Terajima, John Cruz, Francis Ennis
-
Patent number: 7217526Abstract: The present invention relates to the identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes. Two vaccinia virus CD8+ T cell epitopes restricted by the most common human MHC class I allele, HLA-A0201 have been identified. Both epitopes are highly conserved in vaccinia and variola viruses. The induction of the T cell responses following primary vaccination is demonstrated by the kinetics of epitope specific CD8+ T cells in 3 HLA-A0201 individuals. This information will be useful for the design and analyses of the immunogenicity of experimental vaccinia vaccines, and for basic studies of human T cell memory.Type: GrantFiled: January 26, 2004Date of Patent: May 15, 2007Assignee: University of Massachusetts Medical SchoolInventors: Masanori Terajima, John Cruz, Francis A. Ennis
-
Publication number: 20050277109Abstract: The present invention relates to an in vitro method for determining the ability of a vaccine composition which comprises one or more antigens or a nucleic acid molecule which encodes one or more antigens to stimulate a T cell response.Type: ApplicationFiled: May 13, 2005Publication date: December 15, 2005Applicant: University of Massachusetts Medical CenterInventor: Francis Ennis
-
Patent number: 6962790Abstract: The present invention relates to an in vitro method for determining the ability of a vaccine composition which comprises one or more antigens or a nucleic acid molecule which encodes one or more antigens to stimulate a T cell response.Type: GrantFiled: September 23, 1998Date of Patent: November 8, 2005Assignee: University of Massachusetts Medical CenterInventor: Francis A. Ennis
-
Publication number: 20050129703Abstract: The present invention relates to the identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes. Two vaccinia virus CD8+ T cell epitopes restricted by the most common human MHC class I allele, HLA-A0201 have been identified. Both epitopes are highly conserved in vaccinia and variola viruses. The induction of the T cell responses following primary vaccination is demonstrated by the kinetics of epitope specific CD8+ T cells in 3 HLA-A0201 individuals. This information will be useful for the design and analyses of the immunogenicity of experimental vaccinia vaccines, and for basic studies of human T cell memory.Type: ApplicationFiled: January 26, 2004Publication date: June 16, 2005Applicant: University of Massachusetts Medical CenterInventors: Masanori Terajima, John Cruz, Francis Ennis
-
Patent number: 6627407Abstract: The present invention relates to an in vitro method for determining the ability of a vaccine composition which comprises one or more antigens or a nucleic acid molecule which encodes one or more antigens to stimulate a T cell response.Type: GrantFiled: February 13, 2001Date of Patent: September 30, 2003Assignee: University of Massachusetts Medical CenterInventor: Francis A. Ennis
-
Publication number: 20010055752Abstract: The present invention relates to an in vitro method for determining the ability of a vaccine composition which comprises one or more antigens or a nucleic acid molecule which encodes one or more antigens to stimulate a T cell response.Type: ApplicationFiled: February 13, 2001Publication date: December 27, 2001Applicant: University Massachusetts Medical CenterInventor: Francis A. Ennis
-
Patent number: 5939254Abstract: Specific primers that amplify a portion of the 3'-noncoding regions of dengue virus types 1, 2, 3 and 4, and a method of using these primers in a rapid reverse transcriptase-polymerase chain reaction (RT-PCR) for specific detection of dengue viruses, but not other flaviviruses, is disclosed.Type: GrantFiled: April 28, 1997Date of Patent: August 17, 1999Assignee: University of MassachusettsInventors: Francis A. Ennis, T. Mirawati Sudiro, Hiroaki Ishiko
-
Patent number: 5882650Abstract: This disclosure relates to methods and compositions for stimulating in an individual an influenza A virus protective response which is subtype cross-protective. Influenza A virus NS1 protein, or a T cell epitope thereof, is administered to the individual in an amount sufficient to stimulate the virus protective response.Type: GrantFiled: August 13, 1997Date of Patent: March 16, 1999Assignee: University of Massachusetts Medical CenterInventor: Francis A. Ennis
-
Patent number: 5766601Abstract: This disclosure relates to methods and compositions for stimulating in an individual an influenza A virus protective response which is subtype cross-protective. Influenza A virus NS1 protein, or a T cell epitope thereof, is administered to the individual in an amount sufficient to stimulate the virus protective response.Type: GrantFiled: April 7, 1995Date of Patent: June 16, 1998Assignee: University of Massachusetts Medical CenterInventor: Francis A. Ennis
-
Patent number: 5674502Abstract: This disclosure relates to methods and compositions for stimulating in an individual an influenza A virus protective response which is subtype cross-protective. Influenza A virus NS1 protein, or a T cell epitope thereof, is administered to the individual in an amount sufficient to stimulate the virus protective response.Type: GrantFiled: June 5, 1995Date of Patent: October 7, 1997Assignee: University of Massachusetts Medical CenterInventor: Francis A. Ennis